GABAA receptor negative allosteric modulator

Latest Updates of 7 Viva's Portfolio Companies

Retrieved on: 
금요일, 7월 28, 2023
Dai, FALCON, Head, Acquisition, Patient, Fabry disease, SUA, Tissue, Pharma, Gout, Therapy, Heart failure, CSO, GABAA receptor negative allosteric modulator, Research, NAM, VBI, Small RNA, Medicine, Liver, Growth, CIO, Listeria monocytogenes non-coding RNA, Phase, FDA, URAT1, G protein-coupled receptor, SRT, PAR2, DSM-IV codes, Gq alpha subunit, Glaucoma, Ocular hypertension, SAN, Mercury (element), Allosteric regulation, IOP, Flare, Central nervous system, Drug development, Quality of life, Facet joint arthrosis, RNA, Novartis, Cardiology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Fine chemical, Riparian zone, Domain, Pfizer

WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Key Points: 
  • WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
  • Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
  • In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
  • DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Retrieved on: 
월요일, 6월 5, 2023
Allosteric regulation, Failure, G protein-coupled receptor, CHUM, Centre hospitalier, Cancer, PAR2, GABAA receptor negative allosteric modulator, Research, CAF, NAM, Immunotherapy, Fibrosis, GPCR, Patient, Neoplasm, EP4, Therapy, Immunosuppression, Gq alpha subunit, Pharmaceutical industry, Vaccine

Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.

Key Points: 
  • Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.
  • PAR2 is a novel therapeutic target in oncology and immuno-oncology, involved in several processes such as tumor proliferation, resistance to immunotherapy and fibrosis.
  • Domain nominated DT-9045 as a first-in-class PAR2 NAM clinical candidate based on its added-value, unique properties and greater therapeutic potential in comparison to biologics targeting PAR2 currently in the clinic by several competitors.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The nomination of our first-in-class PAR2 NAM drug candidate, DT-9045, is an exciting step forward for Domain Therapeutics and for cancer treatment in general.

Quarterly Activities and Cashflow Report

Retrieved on: 
월요일, 1월 30, 2023
Australian Government, Credit, Corporate governance, ASX, PTSD, Bionomics, Non-executive director, Quarter, ADS, BNC210, Evercore, Credit Suisse, Subjective units of distress scale, Executive, Research, Public, CNS, Mass meeting, Evaluation, Conference, SUDS, ACDT, Annual general meeting, BNO, Fireside chats, Social anxiety disorder, Proportionality (law), United Kingdom, Contract research organization, Fireside, Allosteric regulation, KOL, Data, Social anxiety, American College, Safety, GABAA receptor negative allosteric modulator, Central nervous system, Patient, SAD, Annual report, Pharmaceutical industry, Renewable energy, Health insurance, Animal, Management, MD

Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the financial year ended 30 June 2022.

Key Points: 
  • Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the financial year ended 30 June 2022.
  • On 25 October 2022, Bionomics released the Quarterly Activities Report for the quarter ending September 2022.
  • Finally, with the additional financing activities during the quarter, the Company has sufficient cash runway to support its ongoing activities and upcoming milestones with runway to at least mid-2024.
  • A copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

Retrieved on: 
금요일, 12월 2, 2022
Social anxiety disorder, American College of Neuropsychopharmacology, FOR, GABAA receptor negative allosteric modulator, Central nervous system, CNS, Proportionality (law), BNO, Evaluation, Bionomics, Patient, SAD, American College, Allosteric regulation, PTSD, BNC210, Pharmaceutical industry

ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders, today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometrics analysis and drug reformulation of BNC210 for the treatment of PTSD at the 61st Annual meeting of the American College of Neuropsychopharmacology (ACNP) to be held in-person Sunday through Wednesday, December 4-7, 2022 in Phoenix, Arizona.

Key Points: 
  • ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders, today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometrics analysis and drug reformulation of BNC210 for the treatment of PTSD at the 61st Annual meeting of the American College of Neuropsychopharmacology (ACNP) to be held in-person Sunday through Wednesday, December 4-7, 2022 in Phoenix, Arizona.
  • Title: Development of an Improved Oral Tablet Formulation of BNC210, a Negative Allosteric Modulator of the Alpha 7 Nicotinic Acetylcholine Receptor, Suitable for Evaluation as an Acute Treatment for Social Anxiety Disorder.
  • Title: Pharmacometrics Analysis and Drug Reformulation of BNC210 to Optimize its Evaluation in a Phase 2 Trial in PTSD Patients.
  • FOR FURTHER INFORMATION PLEASE CONTACT: